Ozempic

A new study suggests that people who discontinue GLP-1 medications, such as Ozempic and Wegovy, may face an increased risk of heart attack and stroke. The findings add to ongoing debate about how long patients should stay on these widely used weight-loss and diabetes drugs, and whether the cardiovascular benefits persist after stopping treatment.

An obesity medicine doctor is addressing the growing trend of taking small, lower-than-prescribed doses of Ozempic, the weight-loss and diabetes drug semaglutide. The expert explains the potential risks of adjusting doses without medical guidance, including reduced effectiveness and side effects, while noting the limited circumstances where a low dose may genuinely make sense for some patients.

GLP-1 weight-loss drugs such as Ozempic and Wegovy are reshaping sleep medicine, with clinicians reporting improved sleep apnea symptoms in patients losing significant weight and drugmakers seeking apnea indications. Sleep specialists are debating whether medication could reduce reliance on CPAP machines, while researchers caution that long-term effects on sleep disorders remain largely unstudied.